Literature DB >> 19788052

Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.

S Umesh1, A Tandon, V Santosh, B Anandh, S Sampath, B A Chandramouli, V R Sastry Kolluri.   

Abstract

OBJECTIVE: Glioblastomas are the commonest and the most malignant of all adult brain tumors, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior. The utility of tumor markers that reflect their underlying biology is becoming increasingly important with respect to patient prognostication and their potential role as molecular targets of therapy is being recognized. In this study, we aimed to identify the clinical factors and some immunohistochemical markers that could have an effect on patient survival in supratentorial glioblastomas.
MATERIALS AND METHODS: We evaluated 54 cases of adult supratentorial glioblastomas operated over a span of 1 year, with respect to clinical features such as age, Karnofsky performance score (KPS), extent of resection, adjuvant therapy, and immunohistochemical expression of p53, EGFR (Epidermal Growth Factor Receptor) and PTEN (Phosphatase and Tensin homolog).
RESULTS: Radiotherapy and KPS at presentation were significant predictors of outcome in both univariate and multivariate analyses. Among immunohistochemical variables; loss of PTEN expression in association with over-expression of EGFR showed a trend towards poorer survival, in univariate analysis. Over-expression of EGFR and/or p53 emerged as significant predictors of poor outcome on multivariate analysis, despite failing to prognosticate on univariate analysis.
CONCLUSIONS: Our study shows that EGFR and p53 overexpression along with loss of PTEN expression are important adjuncts to clinical variables in prognosticating glioblastoma patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19788052

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  11 in total

1.  Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Authors:  Michael R Zalutsky; Abraham Boskovitz; Chien-Tsun Kuan; Charles N Pegram; Joanne Ayriss; Carol J Wikstrand; Anne F Buckley; Eric S Lipp; James E Herndon; Roger E McLendon; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

2.  Fluorescence lifetime spectroscopy for guided therapy of brain tumors.

Authors:  Pramod V Butte; Adam N Mamelak; Miriam Nuno; Serguei I Bannykh; Keith L Black; Laura Marcu
Journal:  Neuroimage       Date:  2010-11-03       Impact factor: 6.556

3.  Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations.

Authors:  Ce Liu; Yanyang Tu; Xiaoyang Sun; Jian Jiang; Xiaodong Jin; Xiangfei Bo; Zhengming Li; Aimiao Bian; Xiaodong Wang; Dai Liu; Zhengmei Wang; Lianshu Ding
Journal:  Clin Exp Med       Date:  2010-08-31       Impact factor: 3.984

4.  A mechanism for the upregulation of EGF receptor levels in glioblastomas.

Authors:  Jingwen Zhang; Marc A Antonyak; Garima Singh; Richard A Cerione
Journal:  Cell Rep       Date:  2013-06-13       Impact factor: 9.423

5.  Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature.

Authors:  Sudheer R Thumma; Ameer L Elaimy; Nathan Daines; Alexander R Mackay; Wayne T Lamoreaux; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee
Journal:  Case Rep Med       Date:  2012-04-04

Review 6.  Biomarkers for glioblastoma multiforme: status quo.

Authors:  Nicola Montano; Quintino Giorgio D'Alessandris; Alessandro Izzo; Eduardo Fernandez; Roberto Pallini
Journal:  J Clin Transl Res       Date:  2016-03-27

7.  Frequency and Prognosis of Epidermal Growth Factor Receptor Variant III Mutations in Glioblastoma Multiforme among Indian Patients: A Single-Institution Study.

Authors:  Wesley Mannirathil Jose; Vinayak Munirathnam; V Narendranath; Arun Philip; Pavithran Keechilat
Journal:  South Asian J Cancer       Date:  2021-04-26

8.  MAGI3 negatively regulates Wnt/β-catenin signaling and suppresses malignant phenotypes of glioma cells.

Authors:  Qian Ma; Ying Yang; Duiping Feng; Shuai Zheng; Ran Meng; Pengyan Fa; Chunjuan Zhao; Hua Liu; Ran Song; Tao Tao; Longyan Yang; Jie Dai; Songlin Wang; Wen G Jiang; Junqi He
Journal:  Oncotarget       Date:  2015-11-03

9.  Prognostic significance of epidermal growth factor receptor expression in glioma patients.

Authors:  Junhong Li; Ruofei Liang; Chen Song; Yufan Xiang; Yanhui Liu
Journal:  Onco Targets Ther       Date:  2018-02-07       Impact factor: 4.147

10.  EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism.

Authors:  Xing-Chen Chen; Xiang-Tai Wei; Jun-Hong Guan; Hong Shu; Duo Chen
Journal:  Oncotarget       Date:  2017-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.